Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Sihuan Pharmaceutical Holdings Group ( (HK:0460) ).
Sihuan Pharmaceutical announced that its non-wholly-owned subsidiary Xuanzhu Biopharm has completed the full circulation of its H shares, converting 357,245,794 previously unlisted shares into H shares. Following the conversion, Xuanzhu’s entire issued share capital of 517,947,790 shares now trades as H shares on the Hong Kong Stock Exchange.
Xuanzhu Biopharm, listed in Hong Kong since October 2025, focuses on innovative drugs targeting major diseases in digestion, oncology and non-alcoholic steatohepatitis, supported by dual R&D platforms in small molecules and large-molecule biopharmaceuticals. The move to full H share circulation enhances liquidity and market accessibility for Xuanzhu, strengthening Sihuan’s positioning in China’s innovative biopharmaceutical sector and supporting its two-wheel drive strategy in medical aesthetics and biopharma.
More about Sihuan Pharmaceutical Holdings Group
Sihuan Pharmaceutical Holdings Group is an international medical aesthetics and pharmaceutical company founded in 2001 and listed in Hong Kong since 2010. The group operates an innovation-led model with a strong R&D platform, broad global product pipeline, efficient multi-dosage manufacturing and a mature sales network, aiming to become a leading medical aesthetics and biopharmaceutical player in China.
Average Trading Volume: 28,740,971
Technical Sentiment Signal: Buy
Current Market Cap: HK$11.38B
For detailed information about 0460 stock, go to TipRanks’ Stock Analysis page.